Navigation Links
Transcept Pharmaceuticals to Report Second Quarter 2009 Results
Date:8/6/2009

RICHMOND, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will report results for its quarter ended June 30, 2009 on Friday, August 14, 2009, prior to the opening of the market.

A conference call to review the results will begin at 8:30 a.m. ET (5:30 a.m. PT) on August 14, 2009 and will be hosted by Glenn A. Oclassen, President & Chief Executive Officer, and Thomas P. Soloway, Senior Vice President & Chief Financial Officer.

To participate in the conference call, please dial 877-397-0284 (USA) or 719-325-4890 (International). In addition, a dial-up replay of the conference call will be available from August 14, 2009 through August 26, 2009. The replay telephone number is 888-203-1112 (USA) or 719-457-0820 (International), Replay Passcode: 2582954.

A live webcast of the call will also be available from the Investors section on the corporate web site at www.transcept.com. A webcast replay can be accessed on the corporate web site beginning August 14, 2009 at the same time as the conference call and will remain on the site through August 28, 2009.

About Intermezzo(R)

Intermezzo(R) (zolpidem tartrate sublingual tablet), the lead product candidate at Transcept, has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Intermezzo(R) is a sublingual low dose formulation of zolpidem, the active agent most commonly prescribed in the Un
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
2. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
3. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
4. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
5. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
6. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
8. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
9. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
10. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
11. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...sive procedures that provide patients profound rel...is, or sinus infection, are being developed and us...ute. Techniques such as balloon sinuplasty clean ...move any bone or tissue like traditional sinus su...treating sinus symptoms were featured in a recent ...
(Date:11/25/2009)...aremanywaysyoucanimprove,yourhealth,andjustafewsma...econflictingadviceconcerningwhatisgoodforus,andthe...z.comteamhascompiledalistof25health-boostingtips,w...combinationof,oursuggestedactivitieswillboostyourh...emout. , 1.Reduceyourfatintake.Theeffectsoffa...
(Date:11/24/2009)...diation oncologists use advanced imaging technique...magnetic resonance imaging (MRI), and 4-dimensiona...n (to locate the tumor and other areas at risk for...cember issue of the Journal of the American Colle... defining the target, the radiation oncologist dra...
(Date:11/24/2009)...ool of Medicine compared the outcomes of cirrhotic...lcoholic steatohepatitis (NASH) versus alcoholic l...nificant differences in post-transplant survival r...ngs are presented in the December issue of Liver ...ckwell on behalf of the American Association for t...
(Date:11/24/2009)...ty School of Medicine (BUSM) and the Boston Univer...fied a number of proteins whose activation allows ...s with almost 97 percent accuracy. In addition, th...l strategy to analyze this data and specifically i...s) that are active in cancer and "dormant" in norm...
Breaking Medicine News(10 mins):Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 3Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 4Health News:realbuzz.com - Top 25 Ways to Improve Your Health & get a Better Sex Life! 2Health News:New data emerges on liver transplant survival rates 2Health News:New data emerges on liver transplant survival rates 3Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2
...ed goals that may prove elusive even with the aid ...f beauty or fame. Despite repeated setbacks, some ... extraordinary investments of time, emotion, and m...s are low and the costs of continued efforts are h...
...itute researchers have developed a small molecule ... cancer cells into a death signal. The molecule mi... the suicide of some types of cancer cells. ,The ...apy may be less toxic to healthy cells than curren...
...FirstCall/ - Transition Therapeutics Inc.,("Transi... will hold a,conference call on Wednesday, Novembe...uarter fiscal 2008 financial results. Dr. Tony Cru...release to,be issued prior to the call. In order t...
...ldren,s Zero In on Rac1, Rac2 Genes as .... 12 In a study published in the Nov. 13,issue of... Hospital Medical,Center reported that they have d... Rac1 and Rac2, become hyperactive, they prompt a,...
...ma Incorporated,(Nasdaq: VPHM ) today announced t...OMP) of the European Medicines Agency (EMEA) has g...prevention of cytomegalovirus (CMV),disease in pat...y provide significant benefit to patients,sufferin...
...n Cancer Society,is looking for individuals with o...g personal interest in the battle against cancer t...hich researchers should be funded by the,organizat...th cancer, having been a cancer caregiver, or even...
Other Medicine News:Health News:Pursuing parenthood: Discourses of persistence 2Health News:Smac-ing lung cancer to death 2Health News:Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST 2Health News:Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia 2Health News:Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia 3Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 3Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 4Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2
(Date:11/24/2009)...niteMind ,aSaltLakeCitybasedsoftwarecompany,announ...hesoftwareprogramistobeusedinconjunctionwithexisti...edattheCOVDconferencethisOctoberinColorado.Current... eyeQ programaddssignificantvaluetohispractice,Sen...ntstoembedpracticesfromtheofficesettingtothecomfor...
(Date:11/24/2009)...e/--America,spharmaceuticalresearchandbiotechnolog...rpreventHIV/AIDSandrelatedconditions,accordingtoan...dManufacturersofAmerica(PhRMA).December1marksthe21...aignthatoriginatedatthe1988WorldSummitofMinisterso...greatlyencouragedbythesecriticallyimportantmedicin...
(Date:11/24/2009)...uifengBio-Pharmaceutical,Technology,Inc.(OTCBullet...extractsandpharmaceuticalrawmaterialsforuseinpharm...hina,todayreportedthatinits,thirdquarter,thecompan...rthequarterendedSept.30,2009were$4,465,770,anincre...erin2008.Netincome,amountedto1,002,005,or$0.05pers...
Breaking Medicine Technology:Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Liberty Mutual Teen Driving Website Offers New Family Communication Tools to Promote Driving Safety 59744 1Liberty Mutual Teen Driving Website Offers New Family Communication Tools to Promote Driving Safety 59744 2Liberty Mutual Teen Driving Website Offers New Family Communication Tools to Promote Driving Safety 59744 3Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 1Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 3Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 1Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 2Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 3
...SHINGTON, April 29 The recent announcement of the...ssociation annual meeting in Chicago brings optimi... (Avodart), a drug used to treat benign prostatic ...risk of prostate cancer in men with an increased r...ks forward to this becoming an additional tool in ...
...TONY, France, April 29 Stallergenes S.A.,announce...se IIb/III clinical,trial (VO 57.07) on a sublingu...We are very pleased with the outcome of this study...te the efficacy of house dust mites allergen in,tr...he unexpected quick onset,of action and the good s...
Other Medicine Technology:Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer 2Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet 2Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet 3Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet 4
IgE
IgG (sample dilution, 1-shot only) (Liquid)
CRP FULL RANGE (0.1-160 mg/l)
CRP (Complete Kit with Disposible Cards)
Medicine Products: